MALATHION 500EC

EC Classification

F, Flammable R Phase: R10, R 22 diminished vision, ciliary spasm and brow ache. With acute systemic absorption, meiosis may not be evident due to

SECTION 2: Hazards identification

sympathetic discharge in response to the hypertension. In addition to rhinorrhea and hyperemia of the upper respiratory Toxicity class: WHO III; EPA III tract, respiratory effects consist of “tightness” in the chest ADI 0.02 mg/kg and wheezing respiration caused by the combination of NOEL 100 mg/kg (rats) – 21 months bronchoconstriction and increased bronchial secretion. Main Hazard: This compound inhibits cholinesterase Gastrointestinal symptoms occur earliest after ingestion and enzyme activity in the nervous tissue. include anorexia, nausea and vomiting, abdominal cramps, Fire and explosion hazard: and diarrhea. Product is flammable due to the solvent. With percutaneous absorption of liquid, localized sweating Chemical Hazard: and muscular fasciculation in the immediate vicinity are None known. generally the earliest manifestations. Biological Hazard: Inhalation

Principle Routes of Exposure

Skin and eye contact, ingestion Remove source of contamination or move victim to fresh air. and inhalation. Keep affected person warm and at rest. Supply oxygen if necessary. Treat symptomatically and supportively. Seek medical advice immediately. Skin contact: Remove contaminated clothing, shoes and leather goods. Gently wipe of excess chemical. Wash skin gently and thoroughly with water and non-abrasive soap. Seek medical advice if necessary. Persons who become sensitised may require specialised medical management with anti- inflammatory agents. Eye contact: Immediately flush eyes with gently flowing cold water or saline solution for 20 minutes, holding the eyelid(s) open. Seek medical attention immediately. Ingestion: Have victim rinse mouth thoroughly with water. Do not induce vomiting, due to the aromatic solvent. Seek medical advice immediately. Advice to physician: Atropine must be administrated as early as possible and could save lives, if given in time and in an adequate dosage. Patients with organophosphate poisoning require amounts of atropine far in excess of doses usually employed in medical practice.